Ipshita Prakash
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ipshita Prakash has a total of 83 co-authors. Here are the top co-authors by number of shared publications:
Sarkis Meterissian
Department of Surgery, Division of General Surgery, McGill University, Montreal, Canada
7 shared publicationsEricka Iny
McGill University Medical School, Montreal, Canada
6 shared publicationsJean-François Boileau
Department of Surgery, Division of General Surgery, McGill University, Montreal, Canada
6 shared publicationsKaryne Martel
Department of Surgery, Division of General Surgery, McGill University, Montreal, Canada
6 shared publicationsStephanie M. Wong
Department of Surgery, Division of General Surgery, McGill University, Montreal, Canada
6 shared publicationsMark Basik
Department of Surgery, Division of General Surgery, McGill University, Montreal, Canada
5 shared publications
Latest Publications
- Open Access
- 25 April 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (8) , 2063-2070
Five Decades of Innovation—Tailored Breast Cancer Treatment: 1976–2026
- 25 April 2026
- Published by Wiley in World Journal of Surgery
- Vol. 50 (8) , 2063-2070
Open AccessFive Decades of Innovation—Tailored Breast Cancer Treatment: 1976–2026
- 9 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5641-5642
ASO Visual Abstract: Impact of Ethnicity on the Uptake of Risk-Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada
- 9 April 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5641-5642
ASO Visual Abstract: Impact of Ethnicity on the Uptake of Risk-Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada
- 11 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5590-5597
Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada
While several studies have reported on factors influencing the uptake of risk-reducing mastectomy (RRM) in patients with germline pathogenic variants (gPV)
- 11 March 2026
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 33 (6) , 5590-5597
Impact of Ethnicity on the Uptake of Risk Reducing Mastectomy in Unaffected BRCA1/2 and PALB2 Carriers in Canada
While several studies have reported on factors influencing the uptake of risk-reducing mastectomy (RRM) in patients with germline pathogenic variants (gPV)
- Open Access
- 15 November 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 7226-7243
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer
The accurate staging of breast cancer is fundamental for guiding treatment decisions and predicting patient outcomes. However, there can be considerable variation in routine clinical practice based on individual interpretation of guidelines and depending on the healthcare provider initially involved in working up patients newly diagnosed with breast cancer, ranging from primary care providers, triage nurses, surgeons, and/or oncologists. The optimal approach for clinical staging, particularly in asymptomatic patients presenting with intermediate-risk disease, remains a topic of dialogue among clinicians. Given this area of uncertainty, the Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance conducted a modified Delphi process to assess the level of agreement among Canadian expert clinicians on various staging recommendations. In total, 20 items were drafted covering staging based on biological status, the utilization of localization clips, both for the axilla during diagnosis and primary surgical site for margins and radiation therapy planning, and the use of advanced imaging for the investigation of distant metastases. Overall, the consensus threshold among all participants (i.e., ≥75% agreement) was reached in 20/20 items. Differences in clinical practice and recent findings from the literature are provided in the discussion. These consensus recommendations are meant to help standardize breast cancer staging practices in Canada, ensuring accurate diagnosis and optimal treatment planning.
- 15 November 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 7226-7243
Open AccessGuidance for Canadian Breast Cancer Practice: National Consensus Recommendations for Clinical Staging of Patients Newly Diagnosed with Breast Cancer
The accurate staging of breast cancer is fundamental for guiding treatment decisions and predicting patient outcomes. However, there can be considerable variation in routine clinical practice based on individual interpretation of guidelines and depending on the healthcare provider initially involved in working up patients newly diagnosed with breast cancer, ranging from primary care providers, triage nurses, surgeons, and/or oncologists. The optimal approach for clinical staging, particularly in asymptomatic patients presenting with intermediate-risk disease, remains a topic of dialogue among clinicians. Given this area of uncertainty, the Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance conducted a modified Delphi process to assess the level of agreement among Canadian expert clinicians on various staging recommendations. In total, 20 items were drafted covering staging based on biological status, the utilization of localization clips, both for the axilla during diagnosis and primary surgical site for margins and radiation therapy planning, and the use of advanced imaging for the investigation of distant metastases. Overall, the consensus threshold among all participants (i.e., ≥75% agreement) was reached in 20/20 items. Differences in clinical practice and recent findings from the literature are provided in the discussion. These consensus recommendations are meant to help standardize breast cancer staging practices in Canada, ensuring accurate diagnosis and optimal treatment planning.
- Open Access
- 24 October 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6536-6567
Guidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of breast cancer associated with a poor prognosis when sub-optimally treated. Recent advances include new and effective targeted therapies that have significantly improved outcomes for patients. Despite these advances, there are significant gaps across Canada, underscoring the need for evidence-based consensus guidance to inform treatment decisions. Addressing these gaps is crucial to ensuring that effective therapies are integrated into clinical practice, so as to improve the lives of patients affected by this aggressive form of breast cancer. The Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance is a standing nucleus committee of clinical-academic oncologists across Canada and Breast Cancer Canada, a patient organization. The mandate of this group is to provide evidence-based guidance on best practices in the management of patients with breast cancer. These consensus recommendations were developed using a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% of voters agreeing with the recommendation as written. There are 9 recommendations in the early setting; 7 recommendations in the metastatic setting; and 10 recommendations for patients with brain metastases.
- 24 October 2024
- Published by MDPI AG in Current Oncology
- Vol. 31 (11) , 6536-6567
Open AccessGuidance for Canadian Breast Cancer Practice: National Consensus Recommendations for the Systemic Treatment of Patients with HER2+ Breast Cancer in Both the Early and Metastatic Setting
Human epidermal growth factor receptor 2-positive (HER2+) breast cancer is an aggressive subtype of breast cancer associated with a poor prognosis when sub-optimally treated. Recent advances include new and effective targeted therapies that have significantly improved outcomes for patients. Despite these advances, there are significant gaps across Canada, underscoring the need for evidence-based consensus guidance to inform treatment decisions. Addressing these gaps is crucial to ensuring that effective therapies are integrated into clinical practice, so as to improve the lives of patients affected by this aggressive form of breast cancer. The Research Excellence, Active Leadership (REAL) Canadian Breast Cancer Alliance is a standing nucleus committee of clinical-academic oncologists across Canada and Breast Cancer Canada, a patient organization. The mandate of this group is to provide evidence-based guidance on best practices in the management of patients with breast cancer. These consensus recommendations were developed using a modified Delphi process with up to three rounds of anonymous voting. Consensus was defined a priori as ≥75% of voters agreeing with the recommendation as written. There are 9 recommendations in the early setting; 7 recommendations in the metastatic setting; and 10 recommendations for patients with brain metastases.
- 8 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 8132-8133
ASO Visual Abstract: Impact of Margin Status on Local Recurrence in Patients with Breast Cancer Undergoing Breast-Conserving Surgery After Neoadjuvant Chemotherapy: A Retrospective Multi-Institutional Cohort Study
- 8 August 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (12) , 8132-8133
ASO Visual Abstract: Impact of Margin Status on Local Recurrence in Patients with Breast Cancer Undergoing Breast-Conserving Surgery After Neoadjuvant Chemotherapy: A Retrospective Multi-Institutional Cohort Study
- 5 July 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (10) , 6786-6794
Impact of Margin Status on Local Recurrence in Patients with Breast Cancer Undergoing Breast-Conserving Surgery After Neoadjuvant Chemotherapy: A Retrospective Multi-Institutional Cohort Study
Questions have been raised as to an increased risk of local recurrence with breast-conserving surgery (BCS) post NAC highlighting the uncertainty around op
- 5 July 2024
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 31 (10) , 6786-6794
Impact of Margin Status on Local Recurrence in Patients with Breast Cancer Undergoing Breast-Conserving Surgery After Neoadjuvant Chemotherapy: A Retrospective Multi-Institutional Cohort Study
Questions have been raised as to an increased risk of local recurrence with breast-conserving surgery (BCS) post NAC highlighting the uncertainty around op
- Open Access
- 12 April 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (6) , 108324
Timing of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy
- 12 April 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (6) , 108324
Open AccessTiming of genetic testing in BRCA1/2 and PALB2-Associated breast cancer: Preoperative result disclosure increases uptake of risk-reducing mastectomy and reduces unnecessary exposure to radiotherapy
- Open Access
- 12 March 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (6) , 108266
Oncologic safety of breast conserving surgery after neoadjuvant chemotherapy in patients with multiple ipsilateral breast cancer: A retrospective multi-institutional cohort study
- 12 March 2024
- Published by Elsevier in European Journal of Surgical Oncology
- Vol. 50 (6) , 108266
Open AccessOncologic safety of breast conserving surgery after neoadjuvant chemotherapy in patients with multiple ipsilateral breast cancer: A retrospective multi-institutional cohort study
- Open Access
- 20 January 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (6) , 3280
ASO Visual Abstract: Margin Status and Local Recurrence in Phyllodes Tumors of the Breast—A Canadian Series
- 20 January 2023
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 30 (6) , 3280
Open AccessASO Visual Abstract: Margin Status and Local Recurrence in Phyllodes Tumors of the Breast—A Canadian Series